Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

Posted:
28
April 2017

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

The new MHRA accredited unit has been actively running trials in its new surroundings since March 25th with excellent on-going patient feedback.

Our new facility is an early phase specialist unit, it is the fourth unit Richmond Pharmacology has opened and we believe it is our best to date. Richmond Pharmacology completely removed the existing facilities in the building and designed all the floors from scratch creating a better patient experience in the process. The new site has previously been used for conducting early Phase trials for more than 30 years.

It is in an ideal location embedded in the King’s College University and teaching hospital campus."The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market."

Richmond Pharmacology CEO, Dr Jorg Taubel.Our integrated, MHRA licensed clinical trials pharmacy is staffed by an experienced and dedicated team, supervised by two expert QPs providing quality and flexible service, GMP advice and regulatory support to our clients.Located in centre of London, within close walking distance to key transport links, museums, historic attractions and all that London has to offer, Richmond believes the location will offer unrivalled access to patent recruitment enabling Richmond to maintain its position as Market Leaders in Combined Adaptive Early Phase Trials.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more